Zurich Cantonal Bank
ZVRA icon

Zurich Cantonal Bank’s Zevra Therapeutics ZVRA Stock Holding History

Zurich Cantonal Bank’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-916
Closed -$8.21K – 3429
2025
Q4 		$8.21K Buy
+916
New +$8.66K ﹤0.01% 2491

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Zurich Cantonal Bank's ZVRA Position: Q4 2025 in Review

Zurich Cantonal Bank sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 916 shares — an estimated $8.66K sold.

Zurich Cantonal Bank first reported a position in ZVRA in Q1 2025 and held it in 3 quarters. The position peaked at $11.6K in Q2 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Zurich Cantonal Bank reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 916 Zevra Therapeutics shares in Q4 2025, an estimated $8.66K.
  • Zurich Cantonal Bank first reported a position in Zevra Therapeutics in Q1 2025 and held it in 3 quarters.
  • Zurich Cantonal Bank's Zevra Therapeutics position peaked at $11.6K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Zurich Cantonal Bank's 13F filing for Q4 2025, filed 27 Jan 2026.